title: Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma.
abstract: OBJECTIVE
  We report our initial experience with the transarterial chemoembolization (TACE) of unresectable hepatocellular carcinoma (HCC) using cisplatin-conjugated gelatin microspheres (Cis-GMS).
  
  
  METHODS
  Nineteen patients with 25 HCC nodules (mean diameter 23.0 mm) were treated by selective TACE using 50- to 100-μm Cis-GMS. Tumor necrosis and postembolization syndrome were assessed during the follow-up. The tumor response was evaluated on contrast-enhanced computed tomography images at 1 and 3 months after TACE using Cis-GMS.
  
  
  RESULTS
  All procedures were technically successful in all patients; following the TACE using Cis-GMS, there were no major complications, and postembolization syndrome was minimal. At the 1-month follow-up, the response rate was 12 of the 25 (48%) and 21 of the 25 (84%) HCC nodules based on RECIST 1.1 and EASL criteria, respectively; at the 3-month follow-up, it was 10 of the 25 (40%) and 14 of the 25 (56%) HCC nodules, respectively.
  
  
  CONCLUSIONS
  Our initial experience with using Cis-GMS for TACE suggests that these drugs may represent an optimal treatment option for the treatment of advanced HCC and that the use of gelatin microspheres loaded with chemotherapeutic agents warrants further study.
authors.affiliation: Department of Radiology, Shiga University of Medical Science, Seta, Tsukinowa-cho, Otsu, Shiga, Japan. toyama@belle.shiga-med.ac.jp
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Toyama
authors.forename: Norihisa
authors.initials: N
authors.lastname: Nitta
authors.forename: Shinichi
authors.initials: S
authors.lastname: Ohta
authors.forename: Toyohiko
authors.initials: T
authors.lastname: Tanaka
authors.forename: Yukihiro
authors.initials: Y
authors.lastname: Nagatani
authors.forename: Masashi
authors.initials: M
authors.lastname: Takahashi
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Murata
authors.forename: Hisanori
authors.initials: H
authors.lastname: Shiomi
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Naka
authors.forename: Yoshimasa
authors.initials: Y
authors.lastname: Kurumi
authors.forename: Tohru
authors.initials: T
authors.lastname: Tani
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Tabata
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage*; D003287:Contrast Media; D004337:Drug Carriers; D005260:Female; D005500:Follow-Up Studies; D005780:Gelatin; D006801:Humans; D007479:Iopamidol; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D011856:Radiographic Image Enhancement / Q000379:methods; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D003287:Contrast Media; D004337:Drug Carriers; D005780:Gelatin; D007479:Iopamidol; D002945:Cisplatin